title: Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.
abstract: BACKGROUND
  The objective of this study was to evaluate the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on serum magnesium in hypomagnesemic patients with type 2 diabetes.
  
  
  METHODS
  This post hoc analysis was based on pooled data from four placebo-controlled studies of canagliflozin (N = 2313). The proportion of patients with baseline serum magnesium <0.74 mmol/L who achieved serum magnesium ≥0.74 mmol/L at week 26 was evaluated.
  
  
  RESULTS
  At week 26, canagliflozin 100 and 300 mg increased serum magnesium versus placebo in patients with baseline serum magnesium <0.74 mmol/L (17.0% and 19.0% vs 3.9%) and ≥0.74 mmol/L (4.9% and 7.0% vs -1.4%). More patients with baseline serum magnesium <0.74 mmol/L had serum magnesium ≥0.74 mmol/L at week 26 with canagliflozin 100 and 300 mg versus placebo (74.1% and 80.6% vs 28.8%).
  
  
  CONCLUSIONS
  Canagliflozin was associated with normalization of serum magnesium in hypomagnesemic patients with type 2 diabetes, potentially leading to improved cardiometabolic outcomes.
  
  
  BACKGROUND
  ClinicalTrials.gov Identifiers, NCT01081834, NCT01106677, NCT01106625, NCT01106690.
authors.affiliation: St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Gilbert
authors.affiliation: University of California, San Diego, La Jolla, CA, USA.
authors.forename: Christian
authors.initials: C
authors.lastname: Mende
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors.forename: Ujjwala
authors.initials: U
authors.lastname: Vijapurkar
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors.forename: Sue
authors.initials: S
authors.lastname: Sha
authors.affiliation: Janssen Scientific Affairs, LLC, Titusville, NJ, USA. mdavies9@its.jnj.com.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Davies
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors.forename: Mehul
authors.initials: M
authors.lastname: Desai
keywords: Canagliflozin; Cardiometabolic; Cardiovascular disease; Magnesium; Sodium glucose co-transporter; Type 2 diabetes